FACIT and Triphase Accelerator announced a new strategic collaboration with Celgene for a first-in-class preclinical therapeutic targeting the WDR5 protein for the treatment of blood cancers including leukemia.

The Velocity Fund is an investment and grant program that provides over $390,000 in funding each year to Waterloo-area startups.

The Ontario Ministry of Economic Development, Job Creation, and Trade is inviting 12-15 Ontario biotechnology companies to apply to participate in the Ontario Trade Mission to BIO 2019, one of the world’s premier biotech partnering events.   

Mariner Endosurgery announced that the Hamilton General Hospital is the first hospital in the world to acquire Mariner’s LaparoGuard technology, an innovative solution of augmented surgical visualization.

Self Care Catalysts announced the appointment of Dr. Ethan Basch, world-renowned expert in Oncology and Real World Evidence Outcomes Research, as a Scientific Advisor.

ManagingLife announced the re-design and launch of their app, Manage My Pain, now available on the Apple App Store with better usability.

BrainFx will be used by four family health teams in Waterloo-Wellington and a home-care provider, while being studied by Wilfrid Laurier University researchers.

The Consulate General of Canada in Boston is accepting applications for the 2019 Oncology Partnering Initiative, looking for Canadian companies that are developing innovative therapeutics, diagnostics, or research tools addressing needs of companies, researchers or healthcare systems in the oncology space

Cyclica announced the launch of MatchMaker™, a novel deep learning engine which combines molecular biophysics and deep learning to predict binding of new drug molecules to all proteins with high accuracy and high throughput, moving beyond the reliance on molecular docking.

Mobio Interactive's first scientific paper, an active randomised controlled trial, demonstrated that their mindfulness meditation app may provide immediate effects on mood and stress while also providing long-term benefits for attentional control compared to placebo.

Supported by Ontario Genomics, the Genomic Applications Partnership Program (GAPP) funds downstream research and development projects that address real world opportunities and challenges defined by “Receptor” organizations such as industry, government, or not-for-profit entities.

Falcons' Fortunes invites Ontario-based entrepreneurs working in the oncology space to pitch innovative research ideas to a panel of external judges, offering $50,000 in Prospects funding.

Presented by the Impact Centre, Entrepreneurship 100 is an event series aimed at connecting curious people with diverse entrepreneurs, featuring an interactive Q&A conversation and a chance to meet with the panelists.

Winterlight Labs announced a collaboration with Janssen Pharmaceuticals, facilitated by Johnson & Johnson Innovation, which will focus on developing a sensitive digital biomarker that can distinguish patients with mild cognitive impairment, an early stage of Alzheimer's Disease, from healthy elderly subjects. 

Supported by the Ontario Centres of Excellence, the SmartStart Seed Fund supports youth (19-29) entrepreneurs involved in on-campus entrepreneurship activities. Applicants can receive up to $35,000 in seed funding and access to regional business and investment networks and resources.

AmacaThera, a Toronto-based company commercializing hydrogel-based drug delivery platforms, has raised $3.25 million CAD in seed financing from Sprout BioVentures, Viva Biotech, and Grey Sky Venture Partners. 

Synaptive Medical's Evry™, a superconducting, dedicated head-MRI, will be located in the Biomedical Translational Imaging Centre (BIOTIC) and will enable the Evry™ and resulting treatments to be validated against the current standard-of-care and demonstrate its cost-effective impact on Nova Scotia’s health care system.

The Canada Summer Jobs program is a Canadian government grant that offers support for employers providing supervised career-related work experience for youth employees.

Fibrocor Therapeutics and Galapagos NV, a Belgo-Dutch pharmaceutical research company, have announced the formation of a partnership for the development of therapeutics to treat fibrotic diseases of the kidney and other organs.